D-IBS患者中T2DM发病率高是临床亟待解决的难题。目前认为肠道黏膜慢性炎症是D-IBS和T2DM发病的重要机制之一。前期研究提示miR-29b调节sp1/IL-10为D-IBS合并T2DM肠道黏膜炎症反应发生的潜在关键节点。有研究报道健脾中药可减轻肠道黏膜局部炎症反应，在此基础上，本研究拟对180例D-IBS合并T2DM肝郁脾虚证患者用痛泻要方干预前后miR-29b与相关炎症因子相互作用机制的随机、对照的临床研究，在整体及基因水平上，分别建立证侯和方药效应的生物表征模型，探索：① D-IBS合并T2DM患者肝郁脾虚证与炎症反应相关性，miR-29b如何调节sp1/IL-10促进肠道黏膜慢性炎症反应；②疏肝健脾中药是否是通过影响miR-29b调节转录因子参与炎症反应机制实现的？从而揭示古方作用新靶点，为中医中药攻克D-IBS合并T2DM难题开辟新路子。

Given the higher type 2 diabetes mellitus (T2DM) occurrence in patients with diarrhea-predominant irritable bowel syndrome (D-IBS) is a serious trouble in clinic. Chronic intestinal mucosal inflammation is considered one of the important mechanisms of D-IBS and T2DM at present. Our previous studies have suggested that miR-29b regulates Sp1 / IL-10 as a potential key node in the intestinal mucosal inflammatory response of D-IBS combined with T2DM. Some studies have reported that Jianpi herbs can reduce intestinal mucosal local inflammatory response, on this basis, we take the most common syndrome in patients with D-IBS complicated T2DM, the liver depression and spleen deficiency syndrome as a starting point, a randomized, controlled clinical study on the mechanism of interaction between miR-29b and related inflammatory factors in 180 D-IBS patients with T2DM liver depression and spleen deficiency syndrome before and after treatment with traditional Chinese medicine, from the levels of clinic, animal and molecular cell to explore:①The correlation between the liver depression and spleen deficiency syndrome and inflammatory response；how miR-29b regulates sp1 / IL-10 in the pathogenesis of D-IBS with T2DM;②The mechanism of reduction the inflammatory response of Shuganjianpi herbs may reveal new targets of ancient prescriptions. And it is expected to make the TCM syndrome objective and to open a new way to overcome the high recurrence rate of this disease by TCM.